There is currently no medical therapy for Cushing's disease that targets the pituitary adenoma. Availability of such a medical therapy would be a valuable therapeutic option for the management of this disorder.
C
urrently, there is no effective medical therapy that directly targets the ACTH-secreting pituitary adenoma and, thus, the underlying cause of Cushing's disease, although several investigational agents are under evaluation (1) . Peroxisome proliferator-activated receptor-␥ (PPAR-␥) agonists, such as rosiglitazone, initially showed promise as a potential treatment for Cushing's disease (2) (3) (4) , but subsequent studies do not support a routine clinical role for PPAR-␥ agonists in Cushing's disease (5) (6) (7) . Although retinoic acid is effective at reducing ACTH in dogs with Cushing's disease (8) , the effective dose used is high, and human clinical trial results are not currently available. The dopamine D 2 receptor is expressed in more than 75% of corticotroph pituitary adenomas (9) , and a small, short-term study suggested that cabergoline 2-3.5 mg/wk may be effective in treating a subset of patients with Cushing's disease (9) . However, results from long-term studies of cabergoline in patients with Cushing's disease are not available.
The currently available somatostatin analogs octreotide and lanreotide, which are effective in the treatment of acromegaly, are ineffective in Cushing's disease (10 -12) . Octreotide and lanreotide have high affinity for the somatostatin receptor subtype 2 (sst 2 ) and modest affinity for sst 5 . Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with high binding affinity for four of the five known somatostatin receptor subtypes (sst [1] [2] [3] and sst 5 ) and has a 40-fold higher affinity for sst 5 than octreotide (13, 14) . Human corticotroph adenomas express multiple sst receptors, with expression of sst 5 predominating (15) (16) (17) . Pasireotide effectively inhibited ACTH and corticosterone release both in vitro and in vivo, suggesting the potential for effective treatment of Cushing's disease (15, (17) (18) (19) (20) .
This paper presents results from a phase II, proof-of-concept, open-label, short-term multicenter study designed to assess the efficacy, safety, and pharmacokinetics (PK) of pasireotide in patients with de novo, persistent, or recurrent Cushing's disease.
Patients and Methods

Patients
Eligible patients were at least 18 yr of age and had clinically and biochemically confirmed ACTH-dependent Cushing's disease within 2 months of study entry. Cushing's disease was established by the mean of two consecutive 24-h urinary free cortisol (UFC) levels at least two times the upper limit of normal as measured by the local laboratory at each participating center, morning plasma ACTH levels within or above the normal range, and either magnetic resonance imaging confirmation of a pituitary macroadenoma (Ն1 cm) or an inferior petrosal sinus gradient greater than 3 after CRH stimulation. Diagnosis was confirmed by an independent review board of three experts in Cushing's disease, whose primary focus was to confirm that patients enrolled in the study had Cushing's disease of a pituitary source. Patients were required to have a Karnofsky performance status of at least 60 (21) and either have de novo Cushing's disease and be candidates for pituitary surgery or have persistent or recurrent Cushing's disease after surgery without having received any prior pituitary irradiation. Patients must have been able to provide written informed consent to participate and be able to complete 15 d pasireotide treatment.
Key exclusion criteria included Cushing's syndrome due to ectopic ACTH secretion, hypercortisolism secondary to adrenal tumors or nodular (primary) bilateral adrenal hyperplasia, a known inherited syndrome as a cause for ACTH hypersecretion (e.g. Carney complex, MEN-1), and McCune-Albright syndrome. Patients who were not euthyroid, had received octreotide LAR or any other long-acting somatostatin analog within 8 wk of study entry, had poorly controlled diabetes mellitus (presence of ketoacidosis or a glycosylated hemoglobin level Ͼ10%), liver disease, or active gallbladder disease were also ineligible. Patients who were receiving metyrapone or ketoconazole (n ϭ 6) before study entry were required to discontinue treatment with these drugs for 1 and 2 wk, respectively, before receiving pasireotide.
The study was conducted in accordance with the Declaration of Helsinki, and an independent ethics committee or institutional review board for each study site approved the study protocol.
Study design
This was a phase II, proof-of-concept, open-label, single-arm, multicenter study. Patients self-administered pasireotide 600 g sc twice daily (bid) for 15 d at 0900 and 2100 h. Dose adjustments were permitted for patients unable to tolerate the protocol-specified dosage; the dose of pasireotide could be reduced by 150 g per injection at any time if the investigator believed that an ongoing drug-related adverse effect was present.
Endpoints
The primary efficacy outcome was normalization of mean UFC levels after 15 d treatment. Baseline UFC levels were defined as the mean of two 24-h urine specimens collected on d Ϫ2 and Ϫ1. UFC levels at the end of the 15-d study period were measured as the mean of two 24-h urine specimens collected on d 14 and 15. UFC samples, as well as plasma ACTH and serum cortisol samples, were assessed in a central laboratory (Bioanalytical Research Corp. Laboratories, Ghent, Belgium). Treatment was considered successful if the mean posttreatment UFC level was within the normal range [55-276 nmol/24 h (20 -100 g/24 h)]; patients who achieved a normal mean UFC level were considered responders. Secondary endpoints were evaluated by assessing changes in plasma ACTH [normal range, Ͻ10.1 pmol/liter (Ͻ45 pg/ml)] and serum cortisol [normal range, 221-690 nmol/liter (8 -25 g/dl)]. Plasma ACTH and serum cortisol levels were measured on d Ϫ1, 1, 5, 12, and 15 before the morning dose of pasireotide (at 0840 h) and then every 2 h from 1100 -1700 h. The areas under the concentration-time curve (AUC 0 -8h ) for ACTH and serum cortisol were calculated using a trapezoidal method from 0 -8 h (the last sampling time point) by WinNonlin software (version 5.0; Pharsight, Mountain View, CA).
Safety assessments consisted of reporting all adverse events and serious adverse events, with severity graded according to common toxicity criteria (CTC grades 1-4), where grade 1 is a mild event, grade 2 is a moderate event, grade 3 is a severe event, and grade 4 is a life-threatening or disabling event. Assessments included regular monitoring of hematology, blood chemistry, and urinalysis (performed at the central laboratory), and regular assessments of vital signs, electrocardiogram evaluations, physical condition, and body weight. Samples for monitoring blood glucose, insulin, and glucagon levels were collected on d Ϫ1, 1, 5, 12, and 15 before the morning dose of pasireotide and then 2, 4, 6, and 8 h after dose (only the baseline sample was fasting; patients then received a light breakfast, and lunch was given at 4 h).
Hormone assays
Serum cortisol was measured via electrochemiluminescence immunoassay using the Elecsys cortisol reagent kit, with a lower limit of quantification of 0.05 nmol/liter (0.018 g/dl), and intra-and interassay coefficients of variation of 1.2 and 1.4%, respectively. UFC levels were measured via electrochemiluminescence immunoassay using the Elecsys cortisol reagent kit with prior dichloromethane extraction to reduce the amount of cortisol metabolites and conjugates. Plasma ACTH was assayed with the Immulite 2000 ACTH kit, with intra-and interassay coefficients of variation of 7.7 and 8.5%, respectively.
Pharmacokinetics
The pasireotide PK analysis was performed at time 0 (before morning dose), 2, 4, 6, and 8 h after morning dose on d 1, 5, 12, and 15 (end of study). Plasma concentrations of pasireotide were measured using a validated RIA with a lower limit of quantification of 0.04 g/liter. The minimum (trough) plasma concentration (C min ), maximum (peak) plasma concentration (C max ), and time to peak concentration (T max ) were recorded as observed. The AUC 0 -8h was calculated using a trapezoidal method from 0 -8 h (the last sampling time point) by WinNonlin software.
Statistical methods
Patients were accrued in two cohorts using a Simon two-stage design (22) . A cohort of 10 patients was enrolled in the first stage to allow for an early termination of the study in the event of a lack of efficacy of pasireotide. The total planned sample size was 26 patients. A response rate (percentage of patients achieving normalization of UFC levels) of 10% or less was considered unacceptable. The study had at least 90% power to reject the unacceptable response rate of 10% if the true underlying response rate was 35% at a one-sided ␣ ϭ 0.079 level. If at least two patients in the initial cohort of 10 patients were identified as responders, an additional 16 patients would be accrued to the second stage. At the end of the second stage, if at least five patients of the planned 26 patients were responders, pasireotide would be considered effective in the treatment of ACTH-dependent Cushing's disease.
A Student's paired t test was performed for percent change in UFC from baseline and absolute change in UFC from baseline; two-sided P values are reported. A regression model was used to investigate the relationship between end-of-study UFC and baseline UFC; a two-sided P value is shown. The comparison between serum cortisol or plasma ACTH in patients who responded to pasireotide and in those who did not respond was performed by a Student's t test; one-sided P values are reported. Other quantitative and qualitative variables were summarized using descriptive statistics. A 95% confidence interval for the proportion of responders was prepared.
The primary efficacy population included patients who had a baseline mean UFC level above the normal range who had two 24-h urine collections for UFC at baseline and at endpoint and who completed the 15-d treatment period with two or fewer injection interruptions and did not discontinue the study.
Results
A total of 39 patients recruited from 10 centers in five countries received pasireotide treatment (Table 1 ). Of these, 38 patients completed the study; one patient with a preexisting history of diabetes mellitus discontinued treatment because of grade 2 hyperglycemia [blood glucose level Ͼ160 -250 mg/dl (Ͼ8.9 -13.9 mmol/liter)]. The primary efficacy population consisted of 29 patients (Table 1) . Of the 10 patients excluded from the primary efficacy analysis, one patient discontinued before study completion, five patients had fewer than two UFC sample determinations at baseline or study end, and four patients fulfilled inclusion criteria but had a baseline mean UFC level within the normal range of the central laboratory assay (patients were qualified for study entry based on UFC measurements performed at local sites during screening). Nine patients included in the efficacy analysis had a baseline mean UFC level between one and two times the upper limit of the normal range of the central laboratory assay (Table 1 ). However, these nine patients all had two consecutive 24-h UFC measurements more than two times the upper limit of the normal range of the assays used at the local sites during screening, were considered eligible for study entry by the independent review board, and were therefore qualified for inclusion in the efficacy analysis. The safety population consisted of all 39 patients.
Effects of pasireotide on UFC levels
Of the 29 patients included in the primary efficacy population, five (17%) had normalized UFC levels after 15 d treatment with pasireotide (95% confidence interval ϭ 6 -36%). Using the Simon two-stage design, five of the first 26 patients in the primary efficacy population were responders (19%), which met the criterion for study success. Overall, the mean UFC level decreased from baseline by 44.5% (P ϭ 0.021). The mean Ϯ SD UFC level decreased from 1231 Ϯ 1141 nmol/24 h (446 Ϯ 413 
) at study end (P ϭ 0.013). UFC levels decreased in 76% of patients (22 of 29) (Fig. 1) . Seven patients had increased UFC levels at endpoint compared with baseline. Four of the seven patients who had increases in mean UFC levels from baseline to d 15 had 29 -68% decreases in plasma ACTH AUC 0 -8h , which is indicative of discordant results between plasma ACTH and UFC. Figure 2 illustrates the absolute mean UFC levels at baseline and d 15 for each patient. Although a significant correlation between baseline UFC level and UFC level at d 15 was not observed, there was a trend (P ϭ 0.102) toward a lower baseline UFC level being predictive of a response to pasireotide.
Effects of pasireotide on serum cortisol and plasma ACTH levels
At baseline, the mean Ϯ SD AUC 0 -8h of serum cortisol in the primary efficacy population (n ϭ
At baseline, the mean Ϯ SD AUC 0 -8h of plasma ACTH in the primary efficacy population was 123 Ϯ 100 pmol ⅐ h/liter. There was no significant difference in baseline ACTH AUC 0 -8h values between UFC responders (85 Ϯ 31 pmol ⅐ h/liter) and nonresponders (131 Ϯ 108 pmol ⅐ h/liter). At the end of study (d 15), the mean Ϯ SD plasma ACTH AUC 0 -8h was 96 Ϯ 74 pmol ⅐ h/liter and did not show a significant difference between responders 
Safety and tolerability
Thirty-six of the 39 patients (92%) in the safety population experienced one or more adverse event, with 34 patients (87%) considered to have study drug-related adverse events (Table 2) . Most patients (69%) experienced adverse events of mild severity (CTC grade 1). No patient died during the study. Three patients experienced serious adverse events, two of whom had hyperglycemia related to treatment: one with preexisting diabetes mellitus, and one with a known past history of impaired fasting blood glucose or diabetes mellitus. The third patient to experience a serious adverse event had underlying cardiac disease and experienced five cardiac-related events considered to be unrelated to study drug.
The most common adverse events with a suspected study drug relationship (Table 2) were as expected for this class of drug and were predominantly CTC grade 1. The most common events were drug-related gastrointestinal disorders (54% of patients), mainly diarrhea (44%), nausea (23%), and abdominal pain (18%). Six patients experienced a vascular disorder during treatment; five patients reported hypotension, and one patient experienced hot flush. The hypotension lasted for 1-2 d in four of these patients; the fifth patient received dose adjustment. None of the above adverse events caused a patient to discontinue the study. Three patients required dose adjustments because of adverse events: one patient experienced nausea, vomiting, fatigue, and hypotension; one patient experienced diarrhea and nausea; and one patient with a history of diabetes mellitus at baseline developed grade 2 hyperglycemia [blood glucose Ͼ160 -250 mg/dl [Ͼ8.9 -13.9 mmol/liter)] and elected to discontinue the study.
Hyperglycemia occurred in 14 patients (36%). Of these patients, three had a documented medical history of diabetes mellitus and two of impaired fasting glucose at baseline. Most (n ϭ 12) of the 14 patients experienced mild hyperglycemia (grade 1); nine were ongoing events, and three events resolved after 5, 8, and 12 d, respectively. Overall, five patients were treated with oral hypoglycemic agents (including repaglinide or metformin), and two patients were treated with diet alone. Two patients with hyperglycemia had a serious adverse event; one of these events was grade 2 and the other grade 1 [blood glucose levels Ͼ 100 mg/dl (5.6 mmol/liter) but Ͻ160 mg/dl (Ͻ8.9 mmol/liter)]. The patient who experienced the grade 2 event had a medical history of diabetes mellitus at baseline and was receiving antidiabetic medication at that time. She was electively hospitalized and treated with oral hypoglycemics but chose to discontinue the study. The patient with the grade 1 event was hospitalized for observation and received no antidiabetic treatment, and the hyperglycemia resolved within 1 d.
Mean blood glucose levels at baseline and levels observed during treatment with pasireotide showed that increases in blood glucose occurred with initial exposure to injected pasireotide but generally improved to near baseline values by 8 h. Thirty-one patients had normal fasting baseline blood glucose levels [i.e. Ͻ100 mg/dl (Ͻ5.6 mmol/liter)]. Of these, nine patients experienced fasting blood glucose levels of 126 mg/dl or higher (Ն7 mmol/liter) once or more during the course of the 15 d. The hyperglycemic effect was, in general, less pronounced on d 5, 12, and 15 of treatment than on the first day of treatment.
Analysis of insulin and glucagon levels at baseline vs. during treatment indicated that pasireotide administration is followed by initial suppression of insulin but does not significantly influence the pattern of glucagon release. The mean Ϯ SD glucagon level at baseline was 17.5 Ϯ 8.2 pmol/liter, and at d 15 (before dose), it was 17.5 Ϯ 7.8 pmol/liter. The mean insulin level was 120.1 Ϯ 83.4 pmol/liter at baseline and 99.1 Ϯ 67.7 pmol/liter at d 15 (before dose).
PK of pasireotide
Mean Ϯ SD pasireotide plasma concentration vs. time profiles are shown in Fig. 3 , and PK parameters are listed in Table 3 . The PK results indicated that steady-state levels of pasireotide were achieved within 5 d of treatment initiation in patients with Cushing's disease. Drug accumulation was approximately 1.5-and 1.9-fold, based on C max and AUC 0ϭ8h ratios of d 15 (end of study) over d 1, respectively. On d 15, C min , C max , T max , and AUC 0 -8h were 4.9 Ϯ 2.7 g/liter, 21.1 Ϯ 6.9 g/liter, 2 h, and Respiratory, thoracic, and mediastinal disorders 1 (2.6) n ϭ 39. Specific adverse events occurring in at least three patients are also reported.
a Administration-site conditions included erythema, edema, pruritus, and pain.
b Increased alanine aminotransferase and increased ␥-glutamyltransferase.
c Injury and procedural complications included contusion and postprocedural nausea.
98.9 Ϯ 33.9 g ⅐ h/liter, respectively. C max may be underestimated because no plasma samples were collected between 0 (before dose) and 2 h after dose or between 2 and 4 h after dose. The plasma C min and AUC 0 -8h values of pasireotide appeared to be higher in responders than nonresponders. The mean Ϯ SD value of C min in responders (n ϭ 5) was 7.8 Ϯ 4.1 g/liter, which was approximately 1.8 times higher than that in nonresponders 
Discussion
The results from this phase II study demonstrate that at the end of the short treatment period of 15 d, 17% of patients with Cushing's disease had achieved normalized UFC levels, and 76% of patients exhibited reduced UFC levels. A trend toward lower baseline UFC levels being predictive of a response to pasireotide was observed, although such an analysis is hindered by the small patient population in this proof-of-concept study. In addition, reductions in serum cortisol and plasma ACTH were seen during the short-term pasireotide treatment period. There were significantly greater reductions of serum cortisol in UFC responders than nonresponders.
The selected dose for bid sc administration of pasireotide in patients with Cushing's disease was based on PK simulation. In general, 1 g/liter is the concentration at which most neuropeptides (including octreotide) exert pharmacological activity. At the dose level of 600 g sc bid, the peak and trough plasma concentrations of pasireotide at steady state were predicted to be about 15 and about 2 g/liter, respectively. Because plasma protein binding of pasireotide in humans (ϳ88%) is higher than that of octreotide (ϳ65%), the trough plasma concentration of pasireotide required to demonstrate efficacy might be greater than 1 g/liter. Therefore, it was appropriate to use pasireotide 600 g sc bid as a starting dose in this proof-of-concept study in patients with Cushing's disease.
UFC levels in this study were calculated from a mean of two 24-h urine specimens at baseline and at study end. The determination of 24-h UFC is the most direct and reliable index of cortisol secretion. The multiple values help establish the constancy of cortisol secretion over the 24-h period, because there are diurnal variations in plasma levels of corticotropin and cortisol secretion, not only in normal subjects but also in most patients with Cushing's disease (23) (24) (25) . Therefore, in a patient with Cushing's disease, cortisol should be measured in at least two 24-h urine collections. Nonetheless, because of the possible fluctuations in cortisol levels on a day-to-day basis, there is a possibility that some of the observed reductions in UFC levels in this 15-d study may be independent of administration of pasireotide. Conversely, the observed increases in UFC in seven patients may also be a result of episodic rises in cortisol levels and may have been unrelated to or even attenuated by pasireotide.
Pharmacokinetic data for pasireotide in this 15-d study showed an approximately 1.8-fold higher trough plasma concentration (C min ) and a 1.3-fold higher plasma exposure (AUC 0 -8h ) in UFC responders than nonresponders, suggesting that clinical response may be related to pasireotide plasma exposure and that maintaining a pasireotide trough level or plasma exposure above a certain threshold might be important for an optimal clinical response. These preliminary findings need to be confirmed in future studies.
Assessment of corticotroph tumor somatostatin receptor subtype expression in these patients was not undertaken in this study, so it is not known whether variable interpatient expression of sst 2 and sst 5 affected the pasireotide responsiveness.
Somatostatin analogs have been in clinical use for the treatment of acromegaly and carcinoid tumors for over two decades and have a well-established safety profile. Common drug-related adverse events seen with somatostatin analogs include mostly mild-to-moderate and transient injection-site reactions, gastrointestinal disturbances, and hyperglycemia (26) . A similar safety and tolerability profile was seen with pasireotide, and most adverse events were mild and resolved without intervention. Hyperglycemia was observed in 14 patients, and increases in fasting blood glucose appeared to be more notable in patients with a history of impaired fasting blood glucose or diabetes mellitus before receiving pasireotide. In addition, increases in blood glucose occurred with initial exposure to pasireotide, generally improved to near baseline values 8 h after the sc injection, and were in general less pronounced after the first day of treatment, suggesting an attenuation of effect over time may occur, although longer-term data are needed to verify this. Patients who required management for hyperglycemia were responsive to adjustments in oral antidiabetic treatment and/or diet. There were a number of limitations to this study that may have resulted in a bias against a higher response rate. Entry criteria required patients to have moderate or severe Cushing's disease, i.e. UFC levels at least twice the upper limit of normal, which necessitated a greater fall in UFC to reach normal levels than that in patients with mild disease. Additionally, the short study duration, small sample size and sampling time points that may have missed the peak drug effect could have also introduced a bias against a higher rate of responding patients.
In conclusion, sc pasireotide administered for 15 d decreased UFC levels in 76% of patients and normalized UFC levels in five patients with Cushing's disease. Pasireotide was generally well tolerated, with adverse gastrointestinal events being the most common. Blood glucose levels should be monitored during treatment with pasireotide, particularly in patients with preexisting diabetes mellitus or impaired fasting blood glucose. Steady-state plasma concentrations of pasireotide were achieved within 5 d of treatment, and patients who achieved normalized UFC appeared to have a higher plasma exposure to pasireotide than those who did not. These results demonstrate that pasireotide shows promise as a pituitary-targeted medical treatment for Cushing's disease. Larger studies of longer duration evaluating the efficacy and safety of pasireotide in patients with Cushing's disease are ongoing.
